An evaluation of palbociclib as a breast cancer treatment option: a current update
Author:
Affiliation:
1. Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, School of Medicine, Washington, DC, USA
2. Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA
Funder
funded
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1838485
Reference69 articles.
1. Palbociclib (Ibrance) package insert [Internet]; [cited 2020 Jun 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212436lbl.pdf
2. Cyclin D1 is a nuclear protein required for cell cycle progression in G1.
3. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
4. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4
5. Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Gut microbial β-glucuronidases influence endobiotic homeostasis and are modulated by diverse therapeutics;Cell Host & Microbe;2024-06
2. Targeting p53 misfolding conundrum by stabilizing agents and their analogs in breast cancer therapy: a comprehensive computational analysis;Frontiers in Pharmacology;2024-01-10
3. Induced Endothelial Cell CycleArrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia;Circulation;2023-12-21
4. Outcome in patients of hormone receptor (HR) positive (Her 2) negative metastatic breast cancer treated with palbociclib – A real-world experience;International Journal of Molecular and Immuno Oncology;2022-01-09
5. Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3